Rating #29
Hari Hariharan
Nwi Management
Portfolio value
Stocks
Performance
1 Year
+32.47%
Stock Holdings
$
%
1Y
3Y
5Y
10Y
Hari Hariharan’s Portfolio: Q4 2025
Top10 stocks: 62.99% of the portfolio
Hari Hariharan’s Trades: Q4 2025
Adds
New Buys
Sold Outs
Cuts
0.05ppt
S
Share Count Chg. (%)
Add +1525.20%
2.71ppt
1.70ppt
1.59ppt
1.29ppt
0.27ppt
0.56ppt
0.36ppt
0.04ppt
I
Share Count Chg. (%)
Add +400.00%
0.31ppt
Company Name | Share Count Chg. (%) | Price Paid | Buy Value | Portfolio % Change | |
|---|---|---|---|---|---|
1  LLY | Add +2368.42% | $956.18 | $645.42M | 0.05ppt | |
2 S XLV | Add +1525.20% | $149.77 | $57.11M | 2.71ppt | |
3  MSFT | Add +157.62% | $501.12 | $45.10M | 1.70ppt | |
Add +60.00% | $228.79 | $41.18M | 1.59ppt | ||
5  AVGO | Add +100.00% | $357.61 | $28.97M | 1.29ppt | |
Add +16.67% | $16.07 | $16.07M | 0.27ppt | ||
7  AMZN | Add +176.19% | $228.79 | $12.70M | 0.56ppt | |
8  FIGR | Add +96.64% | $40.00 | $8.00M | 0.36ppt | |
9  META | Add +33.33% | $667.77 | $6.01M | 0.04ppt | |
10 I SLV | Add +400.00% | $50.06 | $5.01M | 0.31ppt |
Hari Hariharan’s Holdings: Q4 2025
Company Name | Primary Industry | Avg. price paid  | Share Count Chg. (%) | No of shares held | Market value | Portfolio % Change | % of Ownership | Holding period | Last Transaction | |
|---|---|---|---|---|---|---|---|---|---|---|
1 I QQQ | - | $614.31 | New Buy +100.00% | 655.20K | $402.50M | 18.53% 18.53ppt | 0.10% | 1 Quarter | Q4 2025 | |
2  NTRA | Medical Laboratories | $135.45 | Cut -8.15% | 762.60K | $174.71M | 8.04% 0.92ppt | 0.56% | 7 Quarters | Q4 2025 | |
3  INSM | Pharmaceutical Pres | $101.09 | Cut -3.19% | 988.46K | $172.03M | 7.92% 0.08ppt | 0.47% | 6 Quarters | Q4 2025 | |
Finance Services | $14.36 | Add +16.67% | 7.00M | $117.18M | 5.40% 0.27ppt | - | 3 Quarters | Q4 2025 | ||
Retail-Catalog & Mail-Order | $223.79 | Add +60.00% | 480.00K | $110.79M | 5.10% 1.59ppt | - | 2 Quarters | Q4 2025 | ||
Prepackaged Software | $483.62 | New Buy +100.00% | 180.00K | $87.05M | 4.01% 4.01ppt | - | 1 Quarter | Q4 2025 | ||
7  MELI | Other Business Services | $1700.44 | 0.00% | 42.70K | $86.01M | 3.96% -1.36ppt | 0.08% | 5 Quarters | Q1 2025 | |
- | $32.98 | 0.00% | 2.50M | $82.13M | 3.78% -0.61ppt | - | 2 Quarters | Q3 2025 | ||
9 MSFT | Prepackaged Software | $442.42 | Add +157.62% | 147.10K | $71.14M | 3.28% 1.70ppt | 0.00% | 26 Quarters | Q4 2025 | |
10  TEVA | Pharmaceutical Pres | $17.97 | 0.00% | 2.07M | $64.45M | 2.97% 0.74ppt | 0.18% | 5 Quarters | Q2 2025 | |
11 S XLV | - | $153.20 | Add +1525.20% | 406.30K | $62.90M | 2.90% 2.71ppt | 0.15% | 10 Quarters | Q4 2025 | |
12  FCX Call | Metal Mining | $50.79 | New Buy +100.00% | 999.30K | $50.75M | 2.34% 2.34ppt | - | 1 Quarter | Q4 2025 | |
13 MELI Call | Other Business Services | $2143.91 | 0.00% | 24.80K | $49.95M | 2.30% -0.79ppt | - | 6 Quarters | Q3 2025 | |
14  TSM | Semiconductors | $303.89 | New Buy +100.00% | 153.00K | $46.50M | 2.14% 2.14ppt | 0.00% | 1 Quarter | Q4 2025 | |
15  IFS | Other Commercial Banks | $41.30 | 0.00% | 1.02M | $43.06M | 1.98% -0.20ppt | 0.93% | 25 Quarters | Q4 2019 | |
16  MU | Semiconductors | $46.06 | Cut -0.69% | 144.00K | $41.10M | 1.89% 0.60ppt | 0.01% | 24 Quarters | Q4 2025 | |
17  NU | Finance Services | $14.87 | Cut -44.98% | 2.20M | $36.85M | 1.70% -1.72ppt | 0.05% | 3 Quarters | Q4 2025 | |
18  GOOG | Computer Programming & Data | $161.49 | Cut -0.90% | 110.00K | $34.52M | 1.59% 0.15ppt | 0.00% | 24 Quarters | Q4 2025 | |
19 AVGO | Semiconductors | $346.10 | Add +100.00% | 81.00K | $28.03M | 1.29% 1.29ppt | 0.00% | 4 Quarters | Q4 2025 | |
20 LLY | Pharmaceutical Pres | $1062.71 | Add +2368.42% | 703.50K | $26.24M | 1.21% 0.05ppt | 0.08% | 5 Quarters | Q4 2025 |
NEWSLETTER
NEWSLETTER
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.
View Data ProvidersOur content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.